Therefore, we hypothesized that reduced expression of B-Myb in colorectal cancer could effectively attenuate the DDR, thereby promoting BTZ-mediated DNA damage and release of DNA damage–associated molecular patterns (DAMPs), leading to immunogenic cell death of the cancer cells. Here, MYBL2 is linked to colorectal cancer.